TMDX241115C200000
- 1.05
- 0.000.00%
TransMedics Newsroom
Earnings Preview: TransMedics to Report Financial Results Post-market on October 28
$TransMedics(TMDX.US)$ is scheduled to release its financial results post-market on October 28 ET. Earnings PreviewAnalysts estimate $TransMedics(TMDX.US)$ to post revenue of USD115.00M for 2024Q3,
With A 25% Price Drop For TransMedics Group, Inc. (NASDAQ:TMDX) You'll Still Get What You Pay For
TransMedics Group (TMDX) Prepare for a Potential Rally as Elliott Wave Signals a Bullish Move
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
TransMedics Group Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since November 2021 -- Data Talk
How Is The Market Feeling About TransMedics Gr?
Dogecoin, Shiba Inu, Pepe May Have Overtaken These Nasdaq-Listed Companies Toward Billion-Dollar Valuations, But There's A Catch
TransMedics to Report Third Quarter 2024 Financial Results on October 28, 2024
Robust Analytical Instrument Segment Likely to Aid TMO's Q3 Earnings
Here's How Much $100 Invested In TransMedics Gr 5 Years Ago Would Be Worth Today
TransMedics Group Inc (TMDX) Q2 2024 Earnings Call Highlights: Record Revenue Growth and ...
Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
TransMedics Group Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $180
Vanguard Group Inc's Strategic Acquisition of TransMedics Group Inc Shares
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $153
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
TD Cowen Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $175
TransMedics Group (TMDX) Buy Rating Affirmed Amid Rising Market Share and Competitive Edge
Looking Into TransMedics Gr's Recent Short Interest